Intracoronary brachytherapy for the treatment of recurrent drug-eluting stent in-stent restenosis: A systematic review and meta-analysis

• Published in: World journal of cardiology 2021-04, Vol.13 (4), p.95-102
• Main Authors: Ilyas, Irtqa, Kumar, Ashish, Adalja, Devina, Shariff, Mariam, Desai, Rupak, Sattar, Yasar, Vallabhajosyula, Saraschandra, Gullapalli, Nageshwara, Doshi, Rajkumar
• Format: Article
• Language: English
• Subjects: Meta-Analysis
• ISSN: 1949-8462; 1949-8462
• DOI: 10.4330/wjc.v13.i4.95

We performed a meta-analysis on observational studies since randomized control trials are not available. We studied intracoronary brachytherapy (ICBT) and recurrent drug eluting stent in-stent restenosis (DES-ISR) to evaluate the procedural success, target lesion revascularization (TLR), incidence of myocardial infarction (MI) and all-cause mortality at 2 years follow-up. To perform meta-analysis for patients undergoing ICBT for recurrent DES-ISR. We performed a systematic search of the PubMed/MEDLINE, Cochrane and DARE databases to identify relevant articles. Studies were excluded if intra-coronary brachytherapy was used as a treatment modality for initial ISR and studies with bare metal stents. We used a random-effect model with DerSimonian & Laird method to calculate summary estimates. Heterogeneity was assessed using statistics. A total of 6 observational studies were included in the final analysis. Procedural angiographic success following intra-coronary brachytherapy was 99.8%. Incidence of MI at 1-year was 2% and 4.1% at 2-years, respectively. The incidence of TLR 14.1% at 1-year and 22.7% at 2-years, respectively. All-cause mortality at 1- and 2-year follow-up was 3% and 7.5%, respectively. Given the observational nature of the studies included in the analysis, heterogeneity was significantly higher for outcomes. While there are no randomized controlled trials or definitive guidelines available for recurrent ISR associated with DES, this analysis suggests that brachytherapy might be the alternative approach for recurrent DES-ISR. Randomized controlled trials are required to confirm results from this study.